Effects of policies and containment measures on control of COVID- 19 epidemic in Chongqing

BACKGROUND Coronavirus disease 2019(COVID-19)is an emerging,rapidly evolving disease that spreads through the respiratory system and is highly contagious.In March 2020,the World Health Organization declared the COVID-19 outbreak a pandemic.In China,the pandemic was controlled after 2 mo through effective policies and containment measures.Describing the detailed policies and containment measures used to control the epidemic in Chongqing will provide a reference for the prevention and control of COVID-19 in other areas of the world.AIM To explore the effects of different policies and containment measures on the control of the COVID-19 epidemic in Chongqing.METHODS Epidemiological data on COVID-19 in Chongqing were prospectively collected from January 21 to March 15,2020.The policies and prevention measures implemented by the government during the epidemic period were also collected.Trend analysis was performed to explore the impact of the main policy measures on the effectiveness of the control of COVID-19 in Chongqing.As of March 15,the cumulative incidence of COVID-19 in Chongqing was 1.84/100000(576 cases)and the infection fatality rate was 1.04%(6/576).The spread of COVID-19 was controlled by effective policies that involved establishing a group for directing the COVID-19 epidemic control effort;strengthening guidance and supervision;ensuring the supply of daily necessities and medical supplies and equipment to residents;setting up designated hospitals;implementing legal measures;and enhancing health education.Medical techniques were implemented to improve the recovery rate and control the epidemic.Policies such as“the lockdown of Wuhan”,“initiating a first-level response to major public health emergencies”,and“implementing the closed management of residential communities”significantly curbed the spread of COVID-19.Optimizing the diagnosis process,shortening the diagnosis time,and constructing teams of clinical experts facilitated the provision of“one team of medical experts for each patient”treatment for severe patients,which significantly improved the recovery rate and reduced the infection fatality rate.CONCLUSION The prevention policies and containment measures implemented by the government and medical institutions are highly effective in controlling the spread of the epidemic and increasing the recovery rate of COVID-19 patients.

提高实效性临床试验报告的质量——《CONSORT声明》的扩展

近年来实效性临床试验受到更多重视,尤其在传统医学临床评价研究领域。为了提高实效性临床试验报告的质量,CONSORT声明组和医疗保健体系中的实效性随机对照临床试验(pragmatic randomized controlled trials in health care systems,PRACTIHC)小组对《CONSORT声明》进行了修改,以帮助读者评估试验质量和结果的可靠性。实效性试验报告指南,作为《CONSORT声明》的一个特殊扩展,能在报告、评价和应用实效性试验方面帮助编辑、系统评价者、试验设计者和决策者评估实效性试验报告中的信息,判定其结论是否适用,以及干预措施是否可行、可否被接受。2005年1月和2008年3月,在加拿大多伦多分别举行了为期两天的会议来探讨提高随机对照试验对卫生保健决策贡献的方法,焦点集中于实效性试验。2005年会,后扩展版草案修订清单发送至编写组成员,经过几次修订,编写组起草了一份摘要草案。在2008年讨论并修改了这一草案。这份草案发给CONSORT声明组以供修改并发表。这份声明的扩展版提出了对8个条目的补充。及时向国内读者和临床试验研究人员介绍该指南有重要的现实意义和学术价值。北京中医药大学循证医学中心刘建平教授等在短时间内翻译了该指南。本刊希望通过介绍中文版"提高实效性临床试验报告的质量——《CONSORT声明》的扩展"以提高国内实效性临床试验报告的质量,相信也有助于改进试验设计的方法学质量。

Bone morphogenetic protein 4 (BMP4) promotes hepatic glycogen accumulation and reduces glucose level in hepatocytes through mTORC2 signaling pathway

Liver is an important organ for regulating glucose and lipid metabolism.Recent studies have shown that bone morphogenetic proteins(BMPs)may play important roles in regu-lating glucose and lipid metabolism.Inour previous studies,we demonstrated that BMP4 signif-icantly inhibits hepatic steatosis and lowers serum triglycerides,playing a protective role against the progression of non-alcoholic fatty liver disease(NAFLD).However,the direct impact of BMP4 on hepatic glucose metabolism is poorly understood.Here,we investigated the regulatory roles of BMP4 in hepatic glucose metabolism.Through a comprehensive analysis of the 14 types of BMPs,we found that BMP4 was one of the most potent BMPs in promoting hepatic glycogen accumulation,reducing the level of glucose in hepatocytes and effecting the expression of genes related to glucose metabolism.Mechanistically,we demonstrated that BMP4 reduced the hepatic glucose lewels through the activation of mTORC2 signaling pathway in vitro and in wivo.Collectively,our findings strongly suggest that BMP4 may play an essential role in regulating hepatic glucose metabolism.This knowledge should aid us to understand the molecular pathogenesis of NAFLD,and may lead to the development of novel therapeutics by exploiting the inhibitory effects of BMPs on hepatic glucose and lipid metabolism.

更新临床实践指南需要报告的条目：更新版指南的报告清单

目的临床指南需要根据相关研究结果定期审查以确保其可靠性,但在更新临床指南的过程中仍然缺乏对于更新过程表述的优先报告条目。本文旨在介绍更新版指南报告清单(Checklist for the Reporting of Updated Guidelines,Check Up)及其制定过程。方法基于临床指南更新的研究证据的概述,指南研究与评价工具(Appraisal of Guidelines for Research and EvaluationⅡ,AGREEⅡ)和报告清单专家组(33位)的建议开发了初始清单的各条目。然后,使用多个步骤对本清单进行了完善,包括评估10个现有的更新版临床指南,对关键信息提供者进行访谈[应答率为54.2%(13/24)],清单制定专家组内部进行的一个三轮的德尔菲(Delphi)共识调查,以及来自于临床指南方法学专家[应答率为90%(53/59)]和指南使用者[应答率为55.6%(10/18)]的外部评审意见。结果清单最终包括16个条目,主要涉及:(1)更新版指南的呈现;(2)编辑独立性;(3)更新过程采用的方法。结论更新版指南的报告清单作为一个工具可用于评估更新版指南报告的完整性,并为指南制定者提供撰写报告的要求。

改进实效型试验的报告质量：CONSORT声明的扩充（1）

实效型试验旨在为临床实践决策提供依据，但报告得不好会降低其实用性。CONSORT和Practihc小组描述了对CONSORT指南的修改，帮助读者评估研究结果的适用性。

如何利用FDA药品批文进行证据合成

美国食品药品监督管理局(FDA)公布的可公开获取的批文为深入了解在同行评议的医学期刊上发表的文章所存在的报告偏倚提供了机会1-4。不仅如此,FDA的数据也可直接用于(1)减小此类偏倚对证据合成结果和结论的影响5;(2)获得已发表的临床试验报告中未披露的信息6;(3)以及找出未发表的临床试验等,从而提高对疗效估计的精度7。

East meets West: what opportunities arise in comparing international guidelines for management of cirrhosis?

The management of patients with cirrhosis is complex and subject to ever-evolving literature and recommendations.In the most recent Japanese practice guidelines for liver cirrhosis(1),Yoshiji et al.provide a number of key updates to guidance based on evidence reflective of practice in Japan that are worth emphasizing.